Insider filing
Traded Apr 7 · filed 1 day later
Derivative exercise or conversion — not an open-market buy.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Traded Mar 9, 2026 · Filed Mar 10, 2026
Cytokinetics's Research & Development sold $177K of Cytokinetics shares. The filing references tax withholding.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
open market sale
Code S — open-market or private sale
~$176,513
Shares × reported transaction price
13 days after results of Feb 24, 2026, 57 days before results of May 5, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $62.42 on Mar 9, 2026, 109% above its 52-week low and 11% below its high, after a 2% drop over the previous 30 trading days
52-week range $29.84 (May 15, 2025) to $70.10 (Feb 24, 2026), 81% of the way up, from 251 adjusted closes. 30 trading days earlier: $63.41 on Jan 23, 2026. Describes the past only, not a forecast
RSI 46, 20% above its 200-day average, 2% under its 50-day average, 11% below the 52-week high, 20-day volatility 49% a year, against the S&P 500: +4 points over 1 month, −5 points over 3 months, +13 points over 6 months
From the adjusted closes up to Mar 9, 2026. RSI: Wilder's 14-day relative strength index (0 to 100). Averages: the last 50 and 200 closes. Volatility: standard deviation of the last 20 daily returns, annualised. S&P 500: the stock's move minus SPY's between the same dates (21, 63 and 126 trading days). Describes the past only, not a forecast
Footnote references tax withholding
Only flagged when a footnote says so; never inferred
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | −2.3% | −2.2% | −0.1% |
| 30 days | +2.2% | +0.5% | +1.7% |
| 90 days | +7.6% | +9.0% | −1.4% |
| 180 days | +18.4% | +13.3% | +5.2% |
Past results only. Not a forecast.
Insider filing
Traded Apr 7 · filed 1 day later
Derivative exercise or conversion — not an open-market buy.
Fady Ibraham Malik (EVP Research & Development) sold ~$228K of Cytokinetics
Planned saleInsider filing
Traded Apr 7 · filed 1 day later
Derivative exercise or conversion — not an open-market buy.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.